Company Filing History:
Years Active: 2021-2023
Title: Innovations of Jan Schouten in Antibody Development
Introduction
Jan Schouten is a notable inventor based in Nijmegen, Netherlands. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies for cancer treatment. With a total of 2 patents, Schouten's work focuses on innovative solutions for targeting oncofoetal antigens.
Latest Patents
Schouten's latest patents include groundbreaking inventions related to Anti-5T4 antibodies and antibody-drug conjugates. The first patent describes antibodies against the human 5T4 oncofoetal antigen, which are suitable for clinical trials. These antibodies are cross-reactive for humans and cynomolgus monkeys, exhibiting a strong affinity for the human 5T4 antigen. The invention also discusses the use of these antibodies and corresponding antibody-drug conjugates (ADCs) in treating solid tumors and hematological malignancies. The second patent further elaborates on CDR defined antibodies targeting the 5T4 oncofoetal antigen, emphasizing their binding affinity and potential applications in cancer therapy.
Career Highlights
Jan Schouten is currently associated with Byondis B.V., a company dedicated to advancing innovative therapies in oncology. His work at Byondis has positioned him as a key player in the development of novel antibody-based treatments. Schouten's expertise in antibody engineering and drug conjugation has been instrumental in the progress of targeted cancer therapies.
Collaborations
Some of Schouten's notable coworkers include Miranda Maria Cornelia Van Der Lee and Gerardus Joseph Andreas Ariaans. Their collaborative efforts contribute to the innovative research and development initiatives at Byondis B.V.
Conclusion
Jan Schouten's contributions to the field of biotechnology, particularly in the development of Anti-5T4 antibodies and ADCs, highlight his role as a leading inventor in cancer treatment innovations. His work continues to pave the way for advancements in targeted therapies, showcasing the importance of innovation in the medical field.